secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001558370-25-002002
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ArriVent reports FY2024 net loss $80.5M; cash $266.5M; Phase 3 trial enrollment achieved
--------------------------------------------------------------------------------

- Cash and investments of $266.5M as of Dec 31, 2024; expected to fund operations into 2026.
- Net loss $80.5M for FY2024 vs $69.3M in FY2023; R&D expense $79.0M.
- Global pivotal Phase 3 FURVENT study for firmonertinib in EGFR exon20ins NSCLC reached target enrollment of 375 patients.
- Selected next-generation ADC candidate ARR-002 for IND-enabling studies; in-licensed ARR-217 (MRG007) from Lepu Biopharma.
- Plan to provide update on firmonertinib in EGFR PACC mutant NSCLC in H1 2025; top-line Phase 3 data expected in Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000155837025002002/0001558370-25-002002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000155837025002002/avbp-20250303x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-002002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer